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The launch of first-generation protease inhibitors (PIs)
was a major step forward in HCV treatment. However,
this major advance was restricted to genotype 1 (GT-1)
patients. This year the launch of Sofosbuvir a NS5B
nucleotide inhibitor (Nis), Daclatasvir a NS5A inhibitor
(NS5A.I) and Simeprevir a second wave PIs open new
perspective for IFN-free regimen. Both Sofosbuvir and
Daclatasvir have a pan-genotypic activity. Sofosbuvir has
highly potent antiviral activity across all genotypes in
association with pegylated interferon and ribavirin (PR),
thus allowing shortened treatment duration. Moreover,
Sofosbuvir in combination with Daclatasvir without
ribavirin for 12 weeks was able to cure > 95% of naïve
GT-1 and for 24 weeks was able to cure 40 patients
with treatment experienced, failure to triple therapy
with first generation PIs, GT-1 patients. Sofosbuvir in
combination with Simeprevir for 12 weeks without riba-
virin was able to cure all GT-1 naïve patients and over
90% of treatment experienced GT-1 patients. As the
three drugs have potent antiviral activities against GT-4,
such association must be potent in such patient but
data are pending.
For GT-2, Sofosbuvir and ribavirin for 12 weeks are able
to cure > 90% of naïve and treatment-experienced
patients. For GT-3 patients, Sofosbuvir and ribavirin for
24 weeks are able to cure around 90% of naïve and treat-
ment experienced patients with the exception of treat-
ment-experienced cirrhotic patients in whom SVR is
around 60%. However the combination of Sofosbuvir and
Daclatasvir for 24 week leads to more than 90% SVR in
the naïve GT-3 population and trials are on-going for
treatment-experienced patients. All this data confirmed
that HCV can be cure with interferon–free regimen and
short duration of treatment. Other combination with
higher efficacy and very good safety profile are under
development and should be available within two years.
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